Corbus Pharmaceuticals Holdings, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $3.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was -$3.53M.
- Corbus Pharmaceuticals Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $5.93M.
- Corbus Pharmaceuticals Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $2.40M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.22M 10-Q · filed 2026-08-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $0.00 derived: sum of 2 quarters · filed 2020-03-16 | -$3.53M derived: sum of 3 quarters · filed 2020-03-16 | $2.40M 10-K · filed 2020-03-16 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$3.53M derived: sum of 2 quarters · filed 2019-11-07 | $2.40M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.40M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $5.93M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |